Correction of experimental dislipoproteinemia by the intranasal administration of an original enzyme preparation

2020 ◽  
Vol 18 (2) ◽  
pp. 155-160
Author(s):  
Natalia N. Klyueva ◽  
Irina V. Okunevich ◽  
Nina S. Parfenova ◽  
Petr D. Shabanov
Keyword(s):  
Enzyme Preparation ◽  
Cholesterol Oxidase ◽  
Serum Lipoprotein ◽  
Lipid Lowering ◽  
Hypolipidemic Effect ◽  
Oxidase Enzyme ◽  
Oxidase Test ◽  
Dose Dependent ◽  
Lipid Lowering Effect ◽  
Selection Of

The article is devoted to the experimental study of the specific pharmacological activity of the original microbial cholesterol oxidase enzyme preparation obtained from Streptomices lavendulae. In the condition of modeling dyslipoproteinemia, a pronounced alimentary hyperlipidemia in rats with the intranasal route of administration, a dose-dependent lipid-lowering effect of the domestic enzyme preparation of microbial origin of cholesterol oxidase was detected. In moderate alimentary hyperlipidemia, based on the selection of animals with a difficultly developed conditioned drinking reflex, this original preparation of cholesterol oxidase in an effective dose has a hypolipidemic effect and normalization of the serum lipoprotein spectrum. Further studies are needed to finally clarify the question of the character, efficacy and hypolipidemic action of the natural-produced cholesterol oxidase test drug in other types of animals.

scholarly journals Effect of lipid-lowering activity of the natural original enzyme preparation in the experiment

2019 ◽  
Vol 65 (3) ◽  
pp. 227-230
Author(s):  
N.N. Klyueva ◽  
I.V. Okunevich ◽  
N.S. Parfenova ◽  
E.V. Belova ◽  
E.V. Ageeva
Keyword(s):  
Experimental Study ◽  
Enzyme Preparation ◽  
Cholesterol Oxidase ◽  
Lipid Lowering ◽  
Good Tolerability ◽  
Microbial Enzyme ◽  
Low Toxicity ◽  
Lowering Activity ◽  
Lipid Lowering Effect

The experimental study in vivo was aimed at evaluation of hypolipidemic action of the original natural microbial enzyme preparation of cholesterol oxidase (CHO). In preliminary chronic experiments in rats, rabbits, dogs, low toxicity, good tolerability, and anti-atherosclerotic activity of the CHO preparation were established. To assess the effect of CHO under conditions of moderate, nutritional, atherogenic dyslipoproteinemia, experiments were carried out in rats, guinea pigs, and rabbits. It was shown that administration of CHO had the pronounced lipid-lowering effect in models of atherogenic dyslipoproteinemia induced in these animals.

scholarly journals Lipid-lowering and anti-atherosclerotic activity of the natural original enzyme preparation in the experiment

2019 ◽  
Vol 17 (3) ◽  
pp. 79-84
Author(s):  
Irina V. Okunevich ◽  
Natalia N. Klyueva ◽  
Nina S. Parfenova ◽  
Elena V. Belova
Keyword(s):  
Large Scale ◽  
Enzyme Preparation ◽  
Cholesterol Oxidase ◽  
Lipid Lowering ◽  
Good Tolerability ◽  
Long Term Study ◽  
Microbial Enzyme ◽  
Low Toxicity

The experimental large-scale investigation in vitro and in vivo is devoted to the results of a long-term study of the biological, lipid-lowering and anti-atherosclerotic activity of the original natural microbial enzyme preparation of cholesterol oxidase (CHO). In chronic experiments (rats, rabbits, dogs), low toxicity, good tolerability, and anti-atherosclerotic activity of the CHO preparation were established. To assess the effect of CHO in conditions of moderate nutritional dyslipoproteinemia, experiments were carried out in 3 species of animals (rats, guinea pigs, rabbits). It was shown the pronounced lipid-lowering effect of CHO in modeling dyslipoproteinemia.

scholarly journals Jiang Tang Xiao Ke Granule, a Classic Chinese Herbal Formula, Improves the Effect of Metformin on Lipid and Glucose Metabolism in Diabetic Mice

2016 ◽  
Vol 2016 ◽  
pp. 1-11 ◽  
Author(s):  
Yi Zhang ◽  
Hong An ◽  
Si-Yuan Pan ◽  
Dan-Dan Zhao ◽  
Jia-Cheng Zuo ◽  
...  
Keyword(s):  
Combination Treatment ◽  
Serum Triglyceride ◽  
Lipid Lowering ◽  
Dependent Manner ◽  
Hepatic Glucose ◽  
Antioxidative Effects ◽  
Antioxidant Stress ◽  
Dose Dependent ◽  
Lipid Lowering Effect

In the present study, the hypoglycemic, hypolipidemic, and antioxidative effects of metformin (MET) combined with Jiang Tang Xiao Ke (JTXK) granule derived from the “Di Huang Tang” were evaluated in mice with type 2 diabetes mellitus (DM) induced by high-fat diet/streptozotocin. DM mice were orally treated with MET (0.19 g/kg) either alone or combined with different doses (1.75, 3.5, or 7 g/kg) of JTXK for 4 weeks. Results showed that the serum and hepatic glucose, lipids, and oxidative stress levels were elevated in DM mice, when compared with the normal mice. MET treatment decreased FBG and serum glucagon levels of DM mice. Combination treatment with MET and JTXK 3.5 g/kg increased the hypoglycemia and insulin sensitivity at 4 weeks when compared with the DM mice treated with MET alone. However, neither MET nor MET/JTXK treatment could completely reverse the hyperglycemia in DM mice. JTXK enhanced the serum triglyceride (TG) and hepatic lipid-lowering effect of MET in a dose-dependent manner in DM mice. JTXK 1.75 and 3.5 g/kg improved the hepatoprotective effect of MET in DM mice. Synergistic effect of combination treatment with MET and JTXK on antioxidant stress was also found in DM mice compared with MET alone.

scholarly journals Relationship between genetic polymorphism of drug transporters and the efficacy of Rosuvastatin, atorvastatin and simvastatin in patients with hyperlipidemia

2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Andrey Sivkov ◽  
Natalya Chernus ◽  
Roman Gorenkov ◽  
Sergey Sivkov ◽  
Svetlana Sivkova ◽  
...  
Keyword(s):  
Genetic Polymorphism ◽  
Drug Transporters ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipid Lowering ◽  
Hypolipidemic Effect ◽  
Low Density Lipoprotein Cholesterol ◽  
Mdr1 Polymorphism ◽  
Lipid Lowering Effect ◽  
Efficacy Of Treatment

Abstract Background To determine the effect of genetic polymorphism of drug transporters on the efficacy of treatment with Rosuvastatin, Atorvastatin and Simvastatin in patients with hyperlipidemia. Methods The study consists of 180 patients, aged 40–75 years, with hyperlipidemia. All patients were divided into two equal groups: patients with different SLCO1B1 (521CC, 521CT and 521TT) and MDR1 (3435CC, 3435TC and 3435TT) genotypes. Each group was divided into rosuvastatin-treated, atorvastatin-treated and simvastatin-treated subgroups. The lipid-lowering effect of statins was assessed by tracing changes in total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) levels. Results The use of statins over a 4-month period led to substantial reductions in TC and LDL-C levels. The hypolipidemic effect of studied agents was seen in both groups. However, it was less pronounced in patients with 521CC genotype. No statistically significantly differences were found between carriers of 3435TT, 3435CT and 3435CC genotypes. Conclusions The lipid-lowering efficacy of rosuvastatin was higher compared to other two statins. Patients with SLCO1B1 521CC genotype are more likely to encounter a decrease in the hypolipidemic effect of statins. Such a risk should be considered when treating this category of patients. MDR1 polymorphism had no significant effect on statin efficacy.

Does chenodesoxycholic acid have a lipid lowering effect in primary hyperlipoproteinemia?

1976 ◽  
Vol 10 (2) ◽  
pp. 147-149 ◽  
Author(s):  
G. Schlierf ◽  
A. Stiehl ◽  
C. C. Heuck ◽  
P. D. Lang ◽  
P. Oster ◽  
...  
Keyword(s):  
Lipid Lowering ◽  
Lowering Effect ◽  
Lipid Lowering Effect

scholarly journals Lipid-lowering effect of tenofovir in HIV-infected patients

2010 ◽  
Vol 66 (3) ◽  
pp. 682-683 ◽  
Author(s):  
M. Fabbiani ◽  
L. Bracciale ◽  
M. Doino ◽  
L. Sidella ◽  
S. Farina ◽  
...  
Keyword(s):  
Lipid Lowering ◽  
Lowering Effect ◽  
Lipid Lowering Effect

Influence of atorvastatin and carboxymethylated glucan on the serum lipoprotein profile and MMP activity of mice with lipemia induced by poloxamer 407

2012 ◽  
Vol 90 (2) ◽  
pp. 141-153 ◽  
Author(s):  
Tatyana A. Korolenko ◽  
Fedor V. Tuzikov ◽  
Marina S. Cherkanova ◽  
Thomas P. Johnston ◽  
Natalia A. Tuzikova ◽  
...  
Keyword(s):  
Total Cholesterol ◽  
Early Stage ◽  
Density Lipoprotein ◽  
Serum Lipoprotein ◽  
Matrix Metalloproteases ◽  
Poloxamer 407 ◽  
Lipid Lowering ◽  
High Dose ◽  
Scattering Method ◽  
Atorvastatin Treatment

The effects of atorvastatin and carboxymethylated β-glucan (CMG) on the lipoprotein-cholesterol (LP-C) and lipoprotein-triglyceride (LP-TG) fractions and subfractions at the early stage of murine hyperlipidemia, and its pleiotropic anti-inflammatory effects, were studied. Atorvastatin and CMG were administered in ICR male mice with acute lipemia induced with a single injection of poloxamer 407 (P-407). A novel small-angle X-ray scattering method for the determination of fractional and subfractional composition of LP-C and LP-TG was used. In P-407-treated animals, there was a drastic increase of total cholesterol and especially TG. Atorvastatin decreased both the total cholesterol and TG, but not to control levels. CMG primarily decreased TG and was not as potent as atorvastatin. P-407 increased atherogenic LDL-C (IDL-C and LDL1–3-C subfractions) and very low-density lipoprotein-C (VLDL-C) (VLDL1–2-C and VLDL3–5-C subfractions) fractions, with an increase of the total anti-atherogenic HDL-C fraction (HDL2-C subfraction). Atorvastatin treatment of lipemia was followed by a decrease in the total LP-C, total LDL-C (LDL1–3-C subfraction), and the LDL1–3-TG subfraction. Additionally, atorvastatin treatment resulted in an increase in the serum matrix metalloproteases activity both in control and P-407-treated mice. In general, high-dose atorvastatin therapy exerts its lipid-lowering and pleiotropic effects in the early stages of acute lipemia induced in mice by treatment with P-407.

Sign in / Sign up

Export Citation Format

Share Document